Vincristine: A new treatment option for Kasabach-Merritt Syndrome

Received: May 17, 2010
Accepted: July 24, 2010
Ref: Avasthi S. Vincristine: a new treatment option for Kasabach-Merritt Syndrome. Internet J Med Update. 2011 Jul;6(2):53-6.

VINCRISTINE: A NEW TREATMENT OPTION FOR KASABACH-MERRITT SYNDROME

Shalini Avasthi MD

Lecturer, Department of Pediatrics, Era,s Medical College, Lucknow, Uttar Pradesh, India

(Corresponding Author: Dr. Shalini Avasthi, Department of Pediatrics, Era,s Medical College, Lucknow, Uttar Pradesh, India; Email: shalini.avasthi@rediffmail.com)

ABSTRACT

Kasabach-Merritt syndrome (KMS) is characterized by a rapidly enlarging hemangioma, thrombocytopenia, microangiopathic hemolytic anemia and consumption coagulopathy as a result of platelet and red blood cell trapping and activation of clotting system within the vasculature of hemangioma. This syndrome is shown to be associated with kaposiform hemangioendotheliomas or tufted hemangioma.

KEY WORDS: Kasabach-Merritt Syndrome; Microangiopathic hemolytic anemia; Thrombocytopenia; Consumption coagulopathy

Note: Some rights reserved. The materials of this electronic journal are copyrighted © by Dr. Arun Kumar Agnihotri “A K S Publication”. No part of this publication may be reproduced by any means without the written permission of the copyright holder. The readers of this journal are free to download, copy, print, distribute and display the work provided; they must give the original author credit, not use this work for commercial purpose, and not alter, transform, or build upon this work.